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Background
In recent years, more and more patients have been treated
with dual antiplatelet therapy (clopidogrel and aspirin),
mainly for acute coronary syndrome or after the placement
of a coronary stent [1]. While this therapy is efficacious in
reducing cardiovascular events, there are some worries
about its safety, in particular regarding the risk of upper
gastrointestinal haemorrhage. In this regard, proton pump
inhibitors (PPI)s reduce the risk of bleeding in patients
treated with low dose aspirin or non-steroidal antinflam-
matory drugs (NSAIDs), and might be an attractive way to
improve the safety of dual antiplatelet therapy [2]. Bio-
logical studies have shown a broad inter-individual vari-
ability of platelet response to clopidogrel, and more
recently, a low response to clopidogrel has been associated
with an increased risk of ischemic events [3]. Several
mechanisms have been proposed to explain this variability
of response, including genetic factors and interaction with
other medications. Clopidogrel is a prodrug converted in
the liver to its active form by cytochrome P450 isoen-
zymes, with the CYP450 isoform 2C19 playing a major
role in this metabolism. There is evidence suggesting that
various PPIs, and most consistently omeprazole [4] can
inhibit CYP2C19, which alters the effectiveness of
clopidogrel, and potentially leads to an increased risk of
adverse cardiovascular outcomes.
Summary
In the COGENT trial [5], 3,873 patients with an indication
for a dual antiplatelet therapy were randomly assigned to
omeprazole or placebo. The primary gastrointestinal (GI)
end point was a composite of overt or occult bleeding,
symptomatic gastroduodenal ulcers or erosions, obstruction
or perforation. The primary cardiovascular end point was a
composite of death from cardiovascular causes, nonfatal
myocardial infarction, revascularization or stroke. Fifty-
one patients presented the primary GI end point, with an
event rate of 1.1% in the omeprazole group and 2.9% in the
placebo group (hazard ratio 0.34, 95% CI 0.18–0.63;
P \ 0.001). The number of patients who would need to be
treated for 6 months to prevent one occurrence of an event
that was part of the primary GI end point is 55.
On the side of safety, 109 patients presented a cardio-
vascular outcome, 4.9% with omeprazole and 5.7% with
placebo (hazard ratio 0.99, 95% CI 0.68–1.44; P = 0.96).
The authors conclude that among patients receiving
aspirin plus clopidogrel, the prophylactic use of a PPI
reduces the rate of upper gastrointestinal bleeding, but the
observed results do not rule out a clinically meaningful
difference in cardiovascular events.
Strengths of the study
• The GI end point is clinically relevant. While finding
endoscopic alterations in patients assuming dual anti-
platelet therapy (used in previous studies) may be
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irrelevant (as it is a surrogate end point), the end point
chosen by the authors is important in daily practice;
• It is a well designed randomized controlled trial for the
purpose of the analysis of the GI end point;
• Although the study is sponsored by industry, all the
analysis and the data management have been indepen-
dently performed by academic scientists.
Weakness of the study
• It is unusual to see two different primary end points in
the same trial. Moreover, while the study is well
designed and conducted for the GI primary end point,
probably a different study design would have been
more appropriate in order to investigate the cardio-
vascular end point. The absence of a significant dif-
ference between the two groups, as the authors state,
cannot rule out a possible meaningful difference for the
primary cardiovascular outcome. The broad CI of the
cardiovascular end point is also in support of this
assertion.
Question marks
It would be interesting to know if the aspirin dose (authors
state that it is between 75 and 325 mg/day) was equal in the
omeprazole and control groups. Indeed this data was not
reported in the article.
Clinical bottom line
Omeprazole reduces the risk of upper gastrointestinal
bleeding in patients with dual antiplatelet therapy. Caution
should be used in patients at high cardiovascular risk
because the cardiovascular results of this trial are not
conclusive.
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